WO2003087329A3 - Targeted cytocidal virionoids for antiangiogenesis - Google Patents

Targeted cytocidal virionoids for antiangiogenesis Download PDF

Info

Publication number
WO2003087329A3
WO2003087329A3 PCT/US2003/011142 US0311142W WO03087329A3 WO 2003087329 A3 WO2003087329 A3 WO 2003087329A3 US 0311142 W US0311142 W US 0311142W WO 03087329 A3 WO03087329 A3 WO 03087329A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
particle
vegf
vegf receptor
preselected
Prior art date
Application number
PCT/US2003/011142
Other languages
French (fr)
Other versions
WO2003087329A2 (en
Inventor
Frederick L Hall
Erlinda M Gordon
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Priority to AU2003230873A priority Critical patent/AU2003230873A1/en
Publication of WO2003087329A2 publication Critical patent/WO2003087329A2/en
Publication of WO2003087329A3 publication Critical patent/WO2003087329A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators

Abstract

The present invention provides an artificial VEGF peptide-bearing non-infectious retroviral particle. The viral particle lacks a fusogenic envelope and is capable of VEGF receptor-mediated binding to endothelial cells of a preselected species. The present invention also provides a method of selectively inhibiting tumor angiogenesis in a mammalian subject by administering to the subject an effective amount of a non-infectious viral particle comprising on its surface a VEGF peptide that specifically binds to a VEGF receptor of the preselected mammalian species. The particle selectively binds to a VEGF receptor-bearing vascular endothelial cell of the subject without delivery of genetic material from the particle. This binding is cytotoxic to the cell and results in a selective inhibition of angiogenesis in a tumor in the subject. The figure illustrates molecular engineering VEGF isoforms into the primary structure of modified MLV envelope proteins.
PCT/US2003/011142 2002-04-11 2003-04-11 Targeted cytocidal virionoids for antiangiogenesis WO2003087329A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003230873A AU2003230873A1 (en) 2002-04-11 2003-04-11 Targeted cytocidal virionoids for antiangiogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37175902P 2002-04-11 2002-04-11
US60/371,759 2002-04-11

Publications (2)

Publication Number Publication Date
WO2003087329A2 WO2003087329A2 (en) 2003-10-23
WO2003087329A3 true WO2003087329A3 (en) 2004-10-28

Family

ID=29250738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011142 WO2003087329A2 (en) 2002-04-11 2003-04-11 Targeted cytocidal virionoids for antiangiogenesis

Country Status (2)

Country Link
AU (1) AU2003230873A1 (en)
WO (1) WO2003087329A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044938A1 (en) * 1997-04-10 1998-10-15 University Of Southern California Modified proteins which bind extracellular matrix components
WO1999055893A1 (en) * 1998-04-29 1999-11-04 University Of Southern California Retroviral vectors including modified envelope escort proteins
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
WO1998044938A1 (en) * 1997-04-10 1998-10-15 University Of Southern California Modified proteins which bind extracellular matrix components
WO1999055893A1 (en) * 1998-04-29 1999-11-04 University Of Southern California Retroviral vectors including modified envelope escort proteins

Also Published As

Publication number Publication date
AU2003230873A8 (en) 2003-10-27
WO2003087329A2 (en) 2003-10-23
AU2003230873A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
WO2006007560A3 (en) Targeted protein replacement for the treatment of lysosomal storage disorders
CN101268102B (en) Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI) -anchors for treatment of cancer and skin lesions
MXPA00010241A (en) Pharmaceutical composition comprising factor viii and neutral liposomes.
CA2095153A1 (en) Genetic modification of endothelial cells
DE3851153D1 (en) GENETIC MODIFICATION OF ENDOTHELIAL CELLS.
WO1999050249A3 (en) Pyrimidines and triazines as integrin antagonists
DE69914932D1 (en) USE OF A CYTOKINE-PRODUCING LACTOCOCCUS TRIBE FOR TREATING COLUMN
WO2000020864A8 (en) Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors
IL129344A0 (en) Novel integrin receptor antagonists
DK0931092T3 (en) Variants of growth factor for vascular endothelial cells with antagonistic properties
EP2008664A3 (en) Modified proteins which bind extracellular matrix components
CA2352286A1 (en) Intracellular targeted delivery of compounds by 70 kd heat shock protein
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
DE3751319T2 (en) USE AND COMPOSITION TO IMPROVE THE "TARGETING" OF ANTIBODIES, ANTIBODY PARTS, AND CONJUGATES THEREOF.
NZ510376A (en) Inhibition of toxic materials or substances, including peptides, proteins and polyamines, using dendrimers
CY1107431T1 (en) PARTICLES FOR GONAL TREATMENT
WO2006052775A3 (en) Peptide anti - tumor agent
WO2003087329A3 (en) Targeted cytocidal virionoids for antiangiogenesis
Strukova Role of platelets and serine proteinases in coupling of blood coagulation and inflammation
DE69730153D1 (en) EHV-1 vectors
ATE372145T1 (en) DELIVERANCE OF GENETIC MATTER TO A STIMULATION SITE
AU7525398A (en) Inhibitors for urokinase receptor
WO2000001802A3 (en) Peptide antagonists of the human urokinase receptor and method for selecting them
WO2001075109A3 (en) Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability
Kern et al. Regulation of gene expression in pancreatic adaptation to nutritional substrates or hormones.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP